Lung Cancer | Specialty

The OncLive Lung Cancer condition center page is a comprehensive resource for clinical news and expert insights on non–small cell lung cancer, small cell lung cancer, mesothelioma, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in lung cancer.

Immunotherapy in Metastatic NSCLC

January 30th 2018

PD-L1 Testing in Metastatic NSCLC

January 30th 2018

Radiotherapy Strategies in Locally Advanced NSCLC

January 30th 2018

Evolving Strategies for Locally Advanced NSCLC

January 30th 2018

Practical Considerations for Immunotherapy in Stage 3 NSCLC

January 30th 2018

Patient Selection for Immunotherapy in NSCLC

January 30th 2018

PACIFIC Trial in Locally Advanced NSCLC

January 30th 2018

Maintenance/Consolidation Therapy in NSCLC

January 30th 2018

Chemoradiotherapy in Unresectable Locally Advanced NSCLC

January 30th 2018

Radiation Therapy in Stage 3 NSCLC

January 30th 2018

Locally Advanced NSCLC: Operable Setting

January 30th 2018

Multimodality Approaches to Locally Advanced NSCLC

January 30th 2018

Treatment of Locally Advanced NSCLC

January 30th 2018

Treatment of Early-Stage NSCLC

January 30th 2018

Dr. Bauml Discusses Liquid Biopsies in Lung Cancer

January 26th 2018

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses the role of liquid biopsies for patients with lung cancer.

Dr. Garon on Sequencing of Agents for Advanced Lung Cancer

January 23rd 2018

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at UCLA, discusses sequencing challenges for patients with advanced lung cancer.

Frontline Pembrolizumab Combo Improves Survival in Phase III NSCLC Trial

January 17th 2018

Combining pembrolizumab with chemotherapy in the frontline setting improved survival in patients with nonsquamous non–small cell lung cancer.

Dr. Erhunmwunsee Discusses Disparities in Lung Cancer Treatment

January 17th 2018

Loretta Erhunmwunsee, MD, thoracic surgeon, assistant professor of surgery, City of Hope, discusses disparities in the treatment of lung cancer.

Bunn Expands on Significance of Atezolizumab/Bevacizumab Regimen in NSCLC

January 16th 2018

Paul A. Bunn, Jr, MD, discusses the IMpower150 study and other immunotherapy combinations in NSCLC.

Hyperprogression Emerges in a Subset of Patients Treated With Immunotherapy

January 16th 2018

Results from a recent multicenter, retrospective analysis of 242 patients with advanced non–small cell lung cancer (NSCLC) found that 16% developed hyperprogression during anti–PD-1/PD-L1 treatment.